These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 17889125

  • 1. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G.
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [Abstract] [Full Text] [Related]

  • 2. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group.
    Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406
    [Abstract] [Full Text] [Related]

  • 3. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar 15; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 6. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May 15; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 7. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D, Cantarovich M, Cecere R, Giannetti N.
    Clin Transplant; 2004 Oct 15; 18(5):493-6. PubMed ID: 15344949
    [Abstract] [Full Text] [Related]

  • 8. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group.
    Transplantation; 2005 Apr 15; 79(7):807-14. PubMed ID: 15818323
    [Abstract] [Full Text] [Related]

  • 9. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
    Figueras J, Bernardos A, Prieto M, Gómez M, Rimola A, Ortiz de Urbina J, Cuervas-Mons V, de la Mata M, Dominguez-Granados R.
    Transplant Proc; 2002 Aug 15; 34(5):1511-3. PubMed ID: 12176461
    [No Abstract] [Full Text] [Related]

  • 10. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2005 Aug 27; 80(4):457-65. PubMed ID: 16123718
    [Abstract] [Full Text] [Related]

  • 11. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 27; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 12. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Transplant; 2003 Jun 27; 17(3):234-41. PubMed ID: 12780674
    [Abstract] [Full Text] [Related]

  • 13. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 14. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
    Figueras J, Prieto M, Bernardos A, Rimola A, Suárez F, de Urbina JO, Cuervas-Mons V, Mata Mde L.
    Transpl Int; 2006 Aug 15; 19(8):641-8. PubMed ID: 16827681
    [Abstract] [Full Text] [Related]

  • 15. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
    Sánchez-Lázaro IJ, Almenar L, Martínez-Dolz L, Buendía-Fuentes F, Agüero J, Navarro-Manchón J, Vicente JL, Salvador A.
    Clin Transplant; 2011 Aug 15; 25(4):606-13. PubMed ID: 20682020
    [Abstract] [Full Text] [Related]

  • 16. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.
    Clin Transplant; 2005 Aug 30; 19(4):475-82. PubMed ID: 16008591
    [Abstract] [Full Text] [Related]

  • 18. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 30; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 19. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ.
    Transplantation; 2001 Nov 27; 72(10):1637-43. PubMed ID: 11726823
    [Abstract] [Full Text] [Related]

  • 20. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May 27; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.